Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)Business Wire • 01/28/21
Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain MutationsBusiness Wire • 01/26/21
Vertex Pharmaceuticals (VRTX) Stock Moves -0.25%: What You Should KnowZacks Investment Research • 01/15/21
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)Seeking Alpha • 01/11/21
Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health CanadaBusiness Wire • 12/28/20